Ascelia Pharma AB (publ) (ticker: ACE) today published its quarterly financial report for Q4 2021 (October – December 2021), which is now available on the company’s website: https://www.ascelia.com/ir-media/financial-reports/
SIGNIFICANT EVENTS IN Q4 2021
- Food Effect Study with Orviglance successfully completed
- FDA approves Investigational New Drug (IND) application for Oncoral clinical development
- Presentation at RSNA of results from Orviglance comparison study to gadolinium
NO SIGNIFICANT EVENTS AFTER THE PERIOD
FINANCIAL SUMMARY Q4 2021
- Operating result of SEK -39.2M (SEK -27.9M)
- Earnings per share of SEK -1.01 (SEK -1.25)
- Cash flow from operations of SEK -32.2M (SEK -27.6M)
- Cash and marketable securities of SEK 261.6M (SEK 184.7M)
FINANCIAL SUMMARY FY 2021
- Operating result of SEK -137.9M (SEK -93.4M)
- Earnings per share of SEK -3.82 (SEK -3.76)
- Cash flow from operations of SEK -116.6M (SEK -85.5M)
- Cash and marketable securities of SEK 261.6M (SEK 184.7M)
“As we now put a busy year behind us, I believe that, despite the effects from the continuing Covid-19 pandemic, we made good progress across our clinical portfolio. Not least in the fourth quarter, when we, among other things, completed the Food Effect study with our diagnostic drug candidate Orviglance®. In December, we presented strong results from a comparison study to a liver-specific gadolinium-based contrast agent. Also, the FDA accepted our Investigational New Drug (IND) application for the upcoming global Phase 2 clinical study in gastric cancer with Oncoral in combination with Taiho Oncology’s LONSURF®”, said Magnus Corfitzen, CEO at Ascelia Pharma.
A presentation for analysts, investors and media will be held today 10 February at 10:00am CET. The event will be hosted by the company’s CEO Magnus Corfitzen, CFO Kristian Borbos, CCO Julie Waras Brogren and VP R&D Andreas Norlin. The presentation will be held in English. The presentation can be followed live via the link: https://tv.streamfabriken.com/ascelia-pharma-q4-2021
It will also be possible to take part of the audiocast afterwards at the same address or at Ascelia Pharma’s website: https://www.ascelia.com/ir-media/financial-reports/
To participate in the telephone conference, please use the dial-in details shown below:
SE: +46 8 505 583 53
UK: +44 333 3009 262
US: +1 646 7224 956
DK: +45 781 501 08